Trastuzumab, Pertuzumab, and Docetaxel vs Trastuzumab Emtansine in ERBB2-Positive Breast Cancer
24.6.2021
0:00
13:01
Interview with Thomas Hatschek, MD, PhD, author of Neoadjuvant Trastuzumab, Pertuzumab, and Docetaxel vs Trastuzumab Emtansine in Patients With ERBB2-Positive Breast Cancer: A Phase 2 Randomized Clinical Trial
Flere episoder fra "JAMA Oncology Author Interviews"
Gå ikke glip af nogen episoder af “JAMA Oncology Author Interviews” - abonnér på podcasten med gratisapp GetPodcast.